Potential-Takeover-Talks Rumors Boost Valeant Pharma (VRX); Total (TOT), Royal Dutch Shell (RDS.A) (RDS.B), Schlumberger (SLB) Battle for Iran Oil and Gas Fields
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shares surged 2.61% (or +0.37) to $14.52 on the last trading session of 2016, following a report from Spanish news website InterEconomia.com indicating that Takeda Pharmaceutical Co. Ltd. (OTCMKTS:TKPYY) has secured the necessary financing – approx. $13 billion – from HSBC and Deutsche Bank to resume takeover talks with the Canadian company.
According to its latest guidance, Valeant expects to deliver full-year 2016 revenue in the range of $9.55 billion to $9.65 billion, and adjusted earnings per share of between $5.30 and $5.50 for the period.
Valeant Pharmaceuticals International, which develops, manufactures, and markets pharmaceuticals, OTC products, and medical devices worldwide, has 341.19M shares outstanding, market capitalization (intraday) of $5.05B and VRX stock 52-week range is from $13.00 to $105.93 per share
The National Iranian Oil Company (NIOC) has published a list of 29 international companies qualified to bid for upstream oil and gas projects in Iran.
The list includes several multinational energy firms, like Total SA (NYSE:TOT), Royal Dutch Shell plc (NYSE:RDS.A) (NYSE:RDS.B) and Schlumberger Ltd. (NYSE:SLB).
The Middle East country believes the new, less restrictive “Iran Petroleum Contract” model, will attract foreign investors and increase oil and gas production – after years of sanctions.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com